HeartLung Corporation's AI-CVD platform receives FDA clearance to detect multiple diseases from a single CT scan.
Key Details
- 1AI-CVD is cleared via FDA 510(k) by HeartLung Corporation.
- 2The platform analyzes CT images of the chest and abdomen to screen for various diseases.
- 3No additional CT sequences, radiation, or contrast are needed to use the tool.
- 4Automatically quantifies clinical measurements for cardiovascular and non-cardiovascular conditions.
- 5Diseases targeted include coronary artery disease, heart failure, atrial fibrillation, stroke, osteoporosis, liver steatosis, and diabetes.
Why It Matters
The clearance marks a significant step for opportunistic AI in radiology, enabling wider disease detection from standard CT scans without extra imaging, doses, or disruptions. This has the potential to improve early diagnosis and make radiology workflows more efficient.
Source
Radiology Business
Related News
•AuntMinnie
GPT-4o AI Matches Radiologists in Follow-Up Imaging Recommendations
GPT-4o matched the performance of experienced radiologists and surpassed residents in recommending follow-up imaging from routine radiology reports.
•Cardiovascular Business
AI Leverages Head CTs for Automated Heart Risk Assessments
AI models can turn routine head CT scans into automated cardiovascular risk assessments, expanding the utility of radiology studies.
•Radiology Business
MRI AI for Parkinsonian Syndrome Gains FDA De Novo Clearance
Neuropacs Corp.'s MRI AI software earns FDA De Novo classification to assist in Parkinsonian syndrome diagnosis.